Article
Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
ACS chemical biology - 18 Dec 2015
Terai Hideki, Tan Li, Beauchamp Ellen M, Hatcher John M, Liu Qingsong, Meyerson Matthew, Gray Nathanael S, Hammerman Peter S
Abstract excerpt
Despite advances in precision medicine approaches over the past decade, the majority of nonsmall cell lung cancers (NSCLCs) are refractory to treatment with targeted small molecule inhibitors. Previous work has identified mutations in the Discoidin Domain Receptor 2 (DDR2) kinase as potential therapeutic targets in NSCLCs. While DDR2 is potently targeted by several multitargeted kinase inhibitors, most notably...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.